Skip to main content

Table 1 Main baseline characteristics of the study population (n = 202) by liver fibrosis stage using transient elastography (TE)

From: Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers

Variable

All patients

Patients with

TE < 7.1 kPa

Patients with

TE ≥ 7.1 kPa

p-value

Mean age, years

47 ± 9

46.7 ± 9

49 ± 9

0.20

Male gender, n (%)

159 (79)

135 (80)

24 (73)

0.36

Caucasian Ethnicity, n (%)

190 (94)

157 (93)

33 (100)

0.87

CD4 count (cells/μl), mean ± SD

591 ± 254

591 ± 240

589 ± 323

0.57

Estimated duration of HIV infection in years, mean ± SD

13 ± 7

13 ± 7

15 ± 6

0.70

HBV co-infection, n (%)

18 (9)

13 (8)

5 (15)

0.18

HCV co-infection, n (%)

35 (17)

16 (10)

19 (58)

< 0.0001

Chronic ALT elevation, n (%)

55 (27)

38 (23)

17 (52)

0.001

Chronic AST elevation, n (%)

38 (19)

19 (11)

19 (58)

< 0.0001

Chronic γ-GT elevation, n (%)

98 (49)

73 (43)

25 (76)

0.001

Exposure to cART, n (%)

179 (89)

148 (88)

31 (94)

0.38

   months on NRTI

    

   mean ± SD

188 ± 135

186 ± 138

199 ± 124

0.60

   months on NNRTI

    

   mean ± SD

36 ± 44

38 ± 47

32 ± 34

0.68

   months on PI

    

   mean ± SD

90 ± 114

83 ± 108

131 ± 135

0.72

   Months on d-drugs

    

   mean ± SD

32 ± 48

27 ± 44

55 ± 64

0.006

BMI (kg/m2), mean ± SD

23.4 ± 3.0

23.2 ± 2.8

24.7 ± 3.7

0.06

HOMA-IR, mean ± SD

2.4 ± 2.3

2.1 ± 1.8

3.8 ± 4.0

0.006

Total serum cholesterol (mg/dl),

    

mean ± SD

203 ± 45

209 ± 45

176 ± 34

< 0.0001

  1. P-values are given for differences between patients with TE values < 7.1 kPa (n = 169) vs. ≥ 7.1 kPa (n = 33)
  2. cART, combination antiretroviral therapy; NRTI nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; d-drugs, stavudine, didanosine, or zalcitabine